Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 321
- Registration Number
- NCT02741245
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in the Treatment of Women With Primary Dysmenorrhea (MK-8342B-060)
Phase 3
Terminated
- Conditions
- Dysmenorrhea
- Interventions
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 18
- Registration Number
- NCT02668822
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in Women With Primary Dysmenorrhea (With Optional Extension) (MK-8342B-059)
Phase 3
Terminated
- Conditions
- Moderate to Severe Primary Dysmenorrhea
- Interventions
- Drug: Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ringDrug: Placebo vaginal ringDrug: Ibuprofen
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 25
- Registration Number
- NCT02668783
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)
Phase 3
Terminated
- Conditions
- Contraception
- Interventions
- Drug: LNG-EE 150 μg/30 μg COCDrug: ENG-E2 125 μg/300 μg vaginal ring
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 2016
- Registration Number
- NCT02616146
- Locations
- 🇦🇹
MSD Osterreich GmbH, Vienna, Austria
🇭🇺MSD Pharma Hungary Kft., Budapest, Hungary
🇩🇪Merck Sharp & Dohme GmbH, Haar, Germany
A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: Ezetimibe 10 mgDrug: Atorvastatin 10 mgDrug: Placebo for Ezetimibe 10 mg tabletBehavioral: Diet control/Daily ExerciseDrug: Placebo for Atorvastatin 10 mg capsule
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 309
- Registration Number
- NCT02550288
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring in Women at Risk for Pregnancy (MK-8342B-061)
Phase 3
Terminated
- Conditions
- Contraception
- Interventions
- Drug: ENG-E2 125 μg/300 μg vaginal ring
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1941
- Registration Number
- NCT02524288
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)
Phase 3
Completed
- Conditions
- Heterozygous Familial HypercholesterolemiaHypercholesterolemia
- Interventions
- Drug: EZ 10 mg/Atorva 10 mg FDCDrug: EZ 10 mg/Atorva 20 mg FDC
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 135
- Registration Number
- NCT02460159
Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204)
Phase 3
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Drug: PlaceboDrug: Desloratadine 5 mg
- First Posted Date
- 2014-12-19
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 449
- Registration Number
- NCT02320396
Performance and Safety of Vaginal Ring Applicator in Healthy Females (MK-8342A-063)
Phase 3
Completed
- Conditions
- Contraception: Optional Applicator for Insertion of Vaginal Ring
- Interventions
- Drug: Placebo vaginal ringDevice: Single-use, non-sterile applicator
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 164
- Registration Number
- NCT02275546
The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168)
Phase 1
Completed
- Conditions
- Osteoarthritis Pain
- Interventions
- Drug: Etoricoxib 75 mg 4% DMSO GelDrug: PlaceboDrug: Etoricoxib 50 mg 4% DMSODrug: Matching Placebo to Etoricoxib 50 mg 4% DMSO GelDrug: Etoricoxib 75 mg 4% PG GelDrug: Etoricoxib 150 mg 4% DMSO GelDrug: Etoricoxib 150 mg 4% PG GelDrug: Etoricoxib 163 mg 4% DMSO gel
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 70
- Registration Number
- NCT01980940
© Copyright 2025. All Rights Reserved by MedPath